Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GENFIT: The FDA Grants Fast Track Designation to GFT505 in NASH

Published: Tuesday, February 18, 2014
Last Updated: Tuesday, February 18, 2014
Bookmark and Share
Granting accelerate the development of GFT505 and reduce the time to market.

GENFIT has announced that the Food and Drug Administration (FDA) has granted Fast Track designation to the GFT505 development program in NASH, with effect from February 14, 2014.

The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to address unmet medical needs.

The aim is to ensure that new therapies for serious conditions are approved and available to patients as soon as possible. This designation permits close and regular contact between GENFIT and the FDA, thus enabling the joint definition of the most efficient development plan through frequent meetings and an accelerated review process.

GENFIT is currently conducting the Phase IIb study GFT505-212-7, for which the primary objective is to demonstrate the efficacy of one year of treatment with GFT505 (80 mg/d and 120 mg/d versus placebo) on the reversion of biopsy-diagnosed NASH. This international study involves a total of 56 centers of clinical excellence in the United States and in multiple European countries.

All patients (a total of 270) have been recruited, more than half have been under treatment for more than 6 months, and the first patients have completed one year of treatment. The results should be announced at the end of 2014.

Commenting on the FDA’s Fast Track designation for GFT505, Jean-François MOUNEY, Chairman and Chief Executive Officer of GENFIT, declared: «All the preclinical and clinical data obtained to date show that GFT505 has the ideal profile for NASH treatment. The granting of the Fast Track designation will enable us to accelerate the development of GFT505 and reduce the time to market.»


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Grants Fast Track Designation to GENFIT's GFT505 in NASH
The aim is to ensure that new therapies for serious conditions are approved and available to patients as soon as possible.
Tuesday, February 18, 2014
GFT505 Reduces the Risk of Cardiovascular Events
Treatment with GFT505 significantly reduces the level of “remnant cholesterol”.
Friday, May 17, 2013
Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic
Genfit has announced that it has achieved a milestone in the therapeutic research collaboration with one of its strategic pharmaceutical partners.
Thursday, May 06, 2010
GENFIT Assembles Four International Experts for it's Scientific Advisory Board
GENFIT, a biopharmaceutical company at the forefront of research and development of drugs, focusing on early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, announces a new Scientific Advisory Board consisting of internationally renowned experts.
Thursday, October 30, 2008
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!